YHLO at WHX Bangkok 2026: Innovation for Better Diagnostics

From July 8 to 10, 2026, WHX Bangkok 2026 was successfully held at the Queen Sirikit National Convention Center in Bangkok, Thailand. As one of Southeast Asia's most influential medical and laboratory events, WHX Bangkok 2026 brought together global exhibitors and industry experts to explore the latest advancements in medical devices, laboratory diagnostics, and smart healthcare. YHLO was proud to be part of this gathering, demonstrating its growing capabilities in multi-disease diagnostic solutions.

YHLO continues to strengthen its focus on diagnostics, covering routine testing and key specialized areas including autoimmunity, reproductive health, diabetes, cardiovascular diseases, liver diseases, kidney diseases, and neurological diseases, with integrated solutions.

In recent years, YHLO has achieved a series of industry-recognized milestones in these fields:

In the cardiovascular diseases field, YHLO's hs-cTnI has been included in the updated list of high-sensitivity cardiac troponin reagent analytical performance references on the official website of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), marking international recognition of the product's performance. Also, YHLO is a key participant in the "14th Five-Year Plan" Chinese key R&D program for high-performance rapid immunoassay point-of-care testing system, advancing China's in-vitro diagnostic technology capabilities.

In the autoimmunity field, YHLO has participated in and led multiple multicenter studies, including the Chinese AntiphosPholipid Syndrome Cohort Collaborative Networks (CAPSTONE). Meanwhile, the company has been actively involved in the "14th Five-Year Plan" Chinese key R&D program — the "Precision Diagnosis and Innovative Therapy Research for Refractory Autoimmune Diseases" project led by Peking Union Medical College Hospital, which is expected to bring breakthrough advances in the precise treatment of refractory autoimmune diseases.

In the liver diseases field, YHLO has established the "YHLO-Peking University Joint Laboratory for Molecular Diagnostics of Infectious Diseases" in collaboration with the team of Academician Zhuang Hui from Peking University, focusing on molecular diagnostic technologies for infectious diseases and striving to deliver innovative outcomes that benefit society and safeguard public health.

In addition, the iTLA mini Plus fully automated biochemistry and immunoassay system was showcased as a key exhibit at the show. With its highly integrated, intelligent, and flexible advantages, it became one of the focal points at the YHLO booth. The system has already been installed in the Americas, Asia-Pacific, and Africa, and installation in the European market is progressing steadily.

The iTLA mini Plus pre-processing unit occupies only 0.99 m², effectively reducing laboratory space requirements while delivering full-process coverage with exceptional space efficiency. The system integrates modules for sample input, centrifugation, decapping, recapping, and sample output, each operating at a speed of 600 tubes per hour. It supports multiple loading methods—pneumatic tube transport, bulk loading, and standard rack-based loading—ensuring seamless workflow integration.

Beyond its compact hardware, the iTLA mini Plus is equipped with visual recognition and intelligent monitoring systems, enabling effective identification of tube types and specifications while supporting quality assurance throughout the testing process. In terms of scalability, the system features a modular architecture that flexibly accommodates 1 to 4 large-scale chemiluminescence analyzers (iFlash 3000, iFlash 9000) and biochemical analyzers, adapting to the throughput needs of various laboratory sizes. Combining flexibility, intelligence, and cost-effectiveness, the iTLA mini Plus offers an ideal choice for laboratory automation upgrades in Southeast Asia.

During the exhibition, the YHLO booth welcomed numerous medical institution representatives and industry partners from Southeast Asia. Both sides engaged in productive discussions on clinical application, regional adaptation, and academic collaboration. Through in-depth exchanges with customers from various countries, the team gained a clearer understanding of the region's pressing needs for laboratory automation and smart transformation.

As WHX Bangkok 2026 draws to a successful close, we extend our heartfelt gratitude to every partner and expert colleague who visited the YHLO booth and shared their stories with us. The path toward more precise and reliable diagnostics is long and demands rigor. In the future, YHLO will continue to work hand in hand with global partners, delivering quality that stands the test of time, and together safeguarding a brighter, healthier future for all.